Clinical trials: B-cell Malignancies
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
- Conditions
- Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL)
- Trial name
- TC011 (NCT07473167)
- Testing
- TC011
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- TICAROS Co., Ltd.
Lymphoma, Large B-Cell, Diffuse
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This is a multicenter China-only study to investigate the PK, efficacy and safety of SC rituximab versus IV rituximab, both in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated…
- Trial name
- NCT04660799
- Testing
- Rituximab IV, Rituximab SC, Cyclophosphamide
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed or refractory low-grade non-Hodgkin's lymphoma.
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT00022581
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the…
- Trial name
- NCT04137900
- Testing
- TAB004, Toripalimab
- Where
- 24 sites in United States
- Volunteers
- 499 people
- Sponsor
- TopAlliance Biosciences
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or…
- Conditions
- Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03685344
- Testing
- Loncastuximab Tesirine and Durvalumab
- Where
- 14 sites in United States, Spain
- Volunteers
- 13 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01307267
- Testing
- PF-05082566, rituximab
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- Pfizer
Mantle Cell Lymphoma, B Cell Lymphoma
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination…
- Trial name
- NCT03478514
- Testing
- Palbociclib, Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Alliance Foundation Trials, LLC.
DLBCL - Diffuse Large B Cell Lymphoma
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a…
- Trial name
- NCT06526065
- Testing
- no intervention
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Medical Center Goettingen
Lymphoma, B-Cell
Retreatment With CTL019/CTL119
This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.
- Trial name
- NCT04419909
- Testing
- CD19 redirected autologous T cells (CTL019 or CTL119 cells)
- Where
- United States
- Sponsor
- University of Pennsylvania
Lymphoma, B-Cell, Lymphoma, Large-Cell, Diffuse
A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
This Phase II study randomized R-ACVBP and R-CHOP as induction treatment in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI.
- Trial name
- LNH2007-3B (NCT00498043)
- Testing
- R-CHOP14 induction regimen, R-ACVBP14 induction regimen
- Where
- France
- Volunteers
- 222 people
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.
- Trial name
- NCT03093168
- Testing
- Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL
This study is focused on tracking the long-term health of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treated with a combination of two drugs, ibrutinib and venetoclax, as part of the…
- Trial name
- I+V-LT (NCT07774390)
- Where
- Italy
- Volunteers
- 323 people
- Sponsor
- European Research Initiative on CLL
Chronic Lymphocytic Leukemia, Frailty
Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia
This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia.
- Conditions
- Chronic Lymphocytic Leukemia, Frailty, Muscle Function, Immune Function
- Trial name
- HIT-CLL (NCT06379282)
- Testing
- HIT, EXE+ Nutritional Guidance
- Where
- United Kingdom
- Volunteers
- 132 people
- Sponsor
- University of Surrey
Follicular Lymphoma, Marginal Zone Lymphoma
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other…
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
- Trial name
- NCT05783596
- Testing
- Obinutuzumab, Glofitamab
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- Reid Merryman, MD
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00720876
- Testing
- rituximab, vorinostat
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
This phase I/Ib trial tests the safety and side effects of asparaginase Erwinia chrysanthemi-recombinant-rywn (recombinant Erwinia asparaginase) and venetoclax in combination with blinatumomab and how well the combination works…
- Trial name
- NCT07133997
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B-cell Lymphoma
R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
To compare the efficacy and safety of chemotherapy alone and combined modality therapy in the treatment of localized CD20 (+) diffuse large B-cell lymphoma
- Trial name
- ASPIRE (NCT02054559)
- Testing
- R-CHOP, Radiotherapy
- Where
- South Korea
- Sponsor
- Asan Medical Center
Chronic Lymphocytic Leukemia, Leukemia
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL).
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia, Neoplasms
- Trial name
- CLL (NCT01657955)
- Testing
- Bendamustine Hydrochloride Injection, Chlorambucil
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd